NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a company developing proprietary carbohydrate-based therapeutic compounds to treat serious diseases such as cancer and fibrosis, today announced it received notice from the American Stock Exchange (“Amex”) staff that the Amex has accepted the Company’s revised compliance plan and will continue the Company’s listing to regain compliance with the continued listing standards. The Company will be subject to periodic review by Amex staff during the plan period. Failure to make progress consistent with the plan, or to regain compliance with the continued listing standards by the end of the plan period, could result in the Company being de-listed from the Amex.
